LLY

984.76

+0.73%↑

JNJ

241.59

-0.56%↓

ABBV

219.68

-2.45%↓

NVS

153.09

-0.73%↓

AZN

190.11

-0.92%↓

LLY

984.76

+0.73%↑

JNJ

241.59

-0.56%↓

ABBV

219.68

-2.45%↓

NVS

153.09

-0.73%↓

AZN

190.11

-0.92%↓

LLY

984.76

+0.73%↑

JNJ

241.59

-0.56%↓

ABBV

219.68

-2.45%↓

NVS

153.09

-0.73%↓

AZN

190.11

-0.92%↓

LLY

984.76

+0.73%↑

JNJ

241.59

-0.56%↓

ABBV

219.68

-2.45%↓

NVS

153.09

-0.73%↓

AZN

190.11

-0.92%↓

LLY

984.76

+0.73%↑

JNJ

241.59

-0.56%↓

ABBV

219.68

-2.45%↓

NVS

153.09

-0.73%↓

AZN

190.11

-0.92%↓

Home・Akcijų sąrašas・Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

442.08 1.09

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

441.06

Max

445.7

Pagrindiniai rodikliai
By Trading Economics
Pajamos	56M -59M
Pardavimai	34M 321M
Pelno marža	-18.243
Darbuotojai	915
EBITDA	56M -50M

Rekomendacijos
By TipRanks
Rekomendacijos	Stiprus pirkimas
12 mėnesių prognozė	+56.84% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-04-30

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	-716M 9.8B
Ankstesnė atidarymo kaina	440.99
Ankstesnė uždarymo kaina	442.08

Naujienos nuotaikos

By Acuity

44%

56%

125 / 351 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Very Strong Bearish Evidence

263.2 / 277.1 Palaikymas ir pasipriešinimas

Madrigal Pharmaceuticals Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-03-13 19:08; UTC

Svarbiausios naujienos

TotalEnergies Shutting Production in Qatar, Iraq Amid Fighting in Middle East

2026-03-13 18:48; UTC

Uždarbis

Pagrindinės rinkos jėgos

Capricor Therapeutics Falls on Wider-Than-Expected 4Q Loss

2026-03-13 17:10; UTC

Svarbiausios naujienos

Week Ahead for FX, Bonds: Central Bank Decisions in Focus After Jump in Energy Prices

2026-03-13 17:10; UTC

Svarbiausios naujienos

Week Ahead for FX, Bonds: Central Bank Decisions -2-

2026-03-13 16:47; UTC

Svarbiausios naujienos

The Week in Oil: Hormuz Crisis Pushes Brent Above $100

2026-03-14 15:00; UTC

Svarbiausios naujienos

Iran War Delivers Windfall to America's Oil Country -- WSJ

2026-03-14 02:03; UTC

Uždarbis

This Copper Stock Is Worth Mining for Profits -- Barrons.com

2026-03-14 01:32; UTC

Įsigijimai, susijungimai, perėmimai

Bill Ackman's Pershing Square IPO Is Back On -- Barrons.com

2026-03-14 00:29; UTC

Įsigijimai, susijungimai, perėmimai

13D Filings -- Barrons.com

2026-03-13 22:27; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Bahrain Faces Uncertainty But Has Support Amid War, S&P Says -- Market Talk

2026-03-13 22:13; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Saudi Arabia Seen as Able to Weather Iran Conflict, S&P Says -- Market Talk

2026-03-13 22:04; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Emirate of RAK Outlook Stable Despite Iran War, S&P Says -- Market Talk

2026-03-13 22:00; UTC

Įsigijimai, susijungimai, perėmimai

Trump Administration Set to Receive $10 Billion Fee for Brokering TikTok Deal -- WSJ

2026-03-13 20:50; UTC

Rinkos pokalbiai

Health Care Roundup: Market Talk

2026-03-13 20:50; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Financial Services Roundup: Market Talk

2026-03-13 20:02; UTC

Rinkos pokalbiai

Canada Rate Hike in 2026 Would Mark 'Extraordinarily Bad' Policy -- Market Talk

2026-03-13 19:50; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Oil Posts Weekly Gains As Middle East Conflict Drags On -- Market Talk

2026-03-13 19:35; UTC

Svarbiausios naujienos

Oil Prices Hover Near $100. India Asks Iran to Allow 23 Tankers Through Strait of Hormuz. -- Barrons.com

2026-03-13 19:00; UTC

Rinkos pokalbiai

U.S. Natural Gas Futures Settle Lower -- Market Talk

2026-03-13 18:49; UTC

Svarbiausios naujienos

The Iran War Could Upend AI. Here's How. -- Barrons.com

2026-03-13 18:24; UTC

Svarbiausios naujienos

Impact of Middle East Conflict on TotalEnergies Activities

2026-03-13 18:00; UTC

Svarbiausios naujienos

Is War Good For the Economy? -- WSJ

2026-03-13 17:23; UTC

Rinkos pokalbiai

U.S. Oil Rig Count Rises by 1 to 412 -- Market Talk

2026-03-13 16:46; UTC

Rinkos pokalbiai

Svarbiausios naujienos

European Indexes End Week Lower as Oil Takes Driving Seat -- Market Talk

2026-03-13 16:38; UTC

Svarbiausios naujienos

Higher Oil Prices Could Bring a Global Economic Shock. This Is the Number to Watch. -- Barrons.com

2026-03-13 16:34; UTC

Įsigijimai, susijungimai, perėmimai

EQT Says It Received Around CHF21 Bln in Total From Galderma Share Sales

2026-03-13 16:33; UTC

Įsigijimai, susijungimai, perėmimai

EQT Receives Proceeds of Around CHF1.3B From Sell-Down

2026-03-13 16:32; UTC

Įsigijimai, susijungimai, perėmimai

EQT Completes Exit From Galderma

2026-03-13 16:20; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Financial Services Roundup: Market Talk

2026-03-13 16:20; UTC

Rinkos pokalbiai

Health Care Roundup: Market Talk

Akcijų palyginimas

Kainos pokytis

Madrigal Pharmaceuticals Inc Prognozė

Kainos tikslas

By TipRanks

56.84% į viršų

12 mėnesių prognozė

Vidutinis 697.67 USD 56.84%

Aukščiausias 964 USD

Žemiausias 529 USD

Remiantis 10 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Madrigal Pharmaceuticals Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

10 ratings

Pirkti

Laikyti

Parduoti

Remiantis 10 analitikų, pateikusių Madrigal Pharmaceuticals Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

263.2 / 277.1Palaikymas ir pasipriešinimas

Bearish events outweigh bullish events.

Recent bearish events outweigh bullish events.

The bullish and bearish events are balanced.

Rinkos nuotaikos

By Acuity

125 / 351 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.